Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 13/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 13/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699806 | 1.00 | ITGB1 (0.46) | ITGB1ITGA4MMP1MMEL1TACR1 | |
| SCHEMBL3695423 | 0.92 | ITGB1 (0.46) | ITGB1ITGA4MMP1MMEL1TACR1 | |
| SCHEMBL3695426 | 0.92 | ITGB1 (0.46) | ITGB1ITGA4MMP1MMEL1TACR1 | |
| SCHEMBL6119336 | 0.89 | ITGA4 (0.41) | ITGB1ITGA4MMP1TACR1MME | |
| SCHEMBL3694685 | 0.84 | ITGB1 (0.40) | ITGB1ITGA4MMP1MME | |
| SCHEMBL3694682 | 0.84 | ITGB1 (0.40) | ITGB1ITGA4MMP1MME | |
| SCHEMBL16214799 | 0.80 | ITGB1 (0.39) | ITGB1ITGA4MMP1MMEL1MME | |
| SCHEMBL3696047 | 0.77 | GHSR (0.47) | ITGB1ITGA4TACR1 | |
| SCHEMBL3698358 | 0.76 | MMP1 (0.66) | ITGB1ITGA4MMP1MME | |
| SCHEMBL3698356 | 0.76 | MMP1 (0.66) | ITGB1ITGA4MMP1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| EP-2640689-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012065953-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | ITGB1 4710/4885ITGA4 4568/4885MMP1 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.